PRACTITION ER UPDATE: Interface between PharmacoepidemioIogy and Pharmacoeconomics in Managed Care Pharmacy
As we will discuss throughout this paper, pharmacoepidemiology is necessary in determining the net gain or effectiveness of a drug therapy, and pharmacoeconomics is interested in comparing those effects and the resources consumed in producing them. 
DEFINITIONS OF TERMS

CONSEQUENCES
Generally, in economic evaluations, consequences are measured in one of three ways: effectiveness, utility, or benefit. These, in turn, relate to the three principal types of economic evaluation: cost-effectiveness analysis, cost -utility analysis, and cost-benefit analysis.
Effectiveness refers to the objective of the therapy or service. The objective may be to prevent or control illness, or it may be to postpone death. In many cost-effectiveness studies in the literature, the measure of effectiveness is "years of life saved" (i.e., the number of lives saved multiplied by the average remaining life expectancy of the patients). To be meaningful, the measure or indicator of effectiveness must be "a common, dominant outcome" relevant for the alternatives being c()mpared; more specifically, the effectiveness measure should capture the "the nature, frequency, and desirability of all the important outcomes of the treatment."8 Given the multitude of outcomes or effects of most therapies, this is not necessarily an easy task. As discussed earlier, the consequence should be measured under "ordinary" circumstances (effectiveness), rather than under "controlled" circumstances (efficacy). When utility is multiplied by years of life, the result is quality-adjusted life-years (QAlYs). This is the measure of consequences in cost-utility studies. Using the utilities in the preceding paragraph, 20 years with mechanical equipment to walk is equivalent to about 16 QAlYs, and 20 years with anxiety/depression/loneliness is equal to 9 QAlYs.
Utility refers to preferences
Benefit is a dollar value assigned to the consequences. Historically, this was done through the human capital approach to valuing life (i.e., earnings or productivity lost through disability or premature death). Recently, benefit is more likely determined through a willingness-to-pay methodology, in which persons are asked how much they would pay to acquire specified positive outcomes or avoid negative ones.12 
USING THE RESULTS
Generally
